T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities Journal Article


Authors: Champlin, R. E.; Passweg, J. R.; Zhang, M. J.; Rowlings, P. A.; Pelz, C. J.; Atkinson, K. A.; Barrett, A. J.; Cahn, J. Y.; Drobyski, W. R.; Gale, R. P.; Goldman, J. M.; Gratwohl, A.; Gordon-Smith, E. C.; Henslee-Downey, P. J.; Herzig, R. H.; Klein, J. P.; Marmont, A. M.; O'Reilly, R. J.; Ringdén, O.; Slavin, S.; Sobocinski, K. A.; Speck, B.; Weiner, R. S.; Horowitz, M. M.
Article Title: T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities
Abstract: T-cell depletion of donor marrow decreases graff-versus-host disease resulting from transplants from unrelated and human leukocyte antigen (HLA)- mismatched related donors. However, there are diverse strategies for T-cell- depleted transplantation, and it is uncertain whether any improve leukemia- free survival (LFS). To compare strategies for T-cell-depleted alternative donor transplants and to compare T-cell depleted with non-T-cell-depleted transplants, we studied 870 patients with leukemia who received T-cell- depleted transplants from unrelated or HLA-mismatched related donors from 1962 to 1994. Outcomes were compared with those of 998 non-T-cell-depleted transplants. We compared LFS using different strategies for T-cell-depleted transplantation considering T-cell depletion technique, intensity of pretransplant conditioning, and posttransplant immune suppression using proportional hazards regression to adjust for other prognostic variables. Five categories of T-cell depletion techniques were considered: narrow- specificity antibodies, broad-specificity antibodies, Campath antibodies, elutriation, and lectins. Strategies resulting in similar LFS were pooled to compare T-cell-depleted with non-T-cell-depleted transplants. Recipients of transplants T-cell depleted by narrow-specificity antibodies had lower treatment failure risk (higher LFS) than recipients of transplants T-cell depleted by other techniques. Compared with non-T-cell-depleted transplants (5-year probability ± 95% confidence interval [CI] of LFS, 31% ± 4%), 5- year LFS was 29% ± 5% (P = NS) after transplants T-cell depleted by narrow- specificity antibodies and 16% ± 4% (P < .0001) after transplants T-cell depleted by other techniques. After alternative donor transplantation, T-cell depletion of donor marrow by narrow-specificity antibodies resulted in LFS rates that were higher than those for transplants T-cell depleted using other techniques but similar to those for non-T-cell-depleted transplants. (C) 2000 by The American Society of Hematology.
Keywords: adolescent; adult; child; child, preschool; middle aged; leukemia; survival rate; retrospective studies; transplantation, homologous; major clinical study; follow-up studies; t lymphocyte; t-lymphocytes; graft failure; hla matching; donor; registries; tissue donors; infant; graft versus host reaction; antibody specificity; immunosuppressive treatment; bone marrow transplantation; graft vs host disease; cyclosporine; immunosuppressive agents; hla antigen; hla antigens; lymphocyte depletion; recipient; histocompatibility testing; t lymphocyte antibody; nuclear family; humans; human; priority journal; article; isoantibodies
Journal Title: Blood
Volume: 95
Issue: 12
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2000-06-15
Start Page: 3996
End Page: 4003
Language: English
PUBMED: 10845940
PROVIDER: scopus
DOI: 10.1182/blood.V95.12.3996
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Richard O'Reilly
    747 O'Reilly